Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.72 ▲ +0.09
(+3.42%)
MKT CAP: $814.3M • VOL: 3.31M
52W L $2 52W H $5
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$2
MEDIAN
$3
MEAN
$3
HIGH
$4
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SANA TAPE
SANA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $3.29 | $3.13 | 2025-02-14 | $2.48 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $3.43 | $3.21 | 2025-02-06 | $2.56 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $3.10 | $2.99 | 2025-01-29 | $2.61 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $2.77 | — | 2025-01-17 | $2.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $2.39 | $2.58 | 2025-01-09 | $2.42 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $3.24 | $2.83 | 2024-12-18 | $2.37 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $2.64 | $2.75 | 2024-12-04 | $2.53 | -4.3% | 48% | C |